QuiaPEG

Investerare

 
Nyheter
Kalender
Aktien
Finansiella rapporter
Dokument
Presentationer
Bolagsstyrning
Organisation
Insynsregister
Analyser
Se nyheter från:
Page:
123456
Mar 12, 2019

QuiaPEG Pharmaceuticals Holding AB (publ.) announces that a patent application within the fast-growing area of antibody drug conjugates* (ADC) has been submitted to the American patent office (USPTO). Granting of the application will mean that QuiaPEG will have patent protection up to and including 2013.

Feb 01, 2019

QuiaPEG Pharmaceuticals Holding AB (publ), "QuiaPEG", today announces that the company has decided on a directed new issue of shares and warrants to three investors.

QuiaPEG Pharmaceuticals Holding AB ("the Company"), listed on Spotlight, today announces that the Company's Board of Directors made the decision on February 1, 2019, with the support of authorization from the Annual General Meeting on June 18, 2018, to carry out a directed new issue of 2,058,824 shares and 2,058,824 warrants.

Dec 18, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that it has successfully registered the Uni-Qleaver® brand name in China.

Dec 11, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that one of the five largest global pharmaceutical companies will place an initial order for activated PEGs (reagents) based on the Uni-Qleaver® platform.

Page:
123456
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message